XTRA:SRT3Life Sciences
Sartorius (XTRA:SRT3) Is Up 14.1% After Upgraded 2025 Guidance Following Strong Q3 Results and MATTEK Deal Has The Bull Case Changed?
Sartorius Aktiengesellschaft has recently reported its third quarter and nine-month results for 2025, highlighted by increased sales to €843.2 million and a rise in net income to €43.8 million, also raising its full-year 2025 financial guidance after considering the MATTEK acquisition and market conditions.
An interesting point is Sartorius' management specifically sharpened its guidance, factoring in strong year-to-date performance, new tariffs, acquisition impact, and comparisons to the...